Drugs / TBX-1400
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02860559 | Aug 2021 → Feb 2024 | severe combined immunodeficiency | Taiga Biotechnologies, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBX-1400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02860559 ↗ |
| Modality | Cell therapy | “This is a study of stem cell transplantation with TBX-1400 in pediatric subjects with severe combined immunodeficiency (SCID).” NCT02860559 ↗ |
| Route | Intravenous | “Single intravenous infusion of TBX-1400” NCT02860559 ↗ |